Reduced All-Cause Mortality in COPD With Budesonide/ Glycopyrrolate/ Formoterol
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate may reduce the risk of death compared with glycopyrrolate/formoterol fumarate in patients with COPD.
Recommendations are presented for the use of noninvasive ventilation for patients with COPD and chronic hypercapnia in an American Thoracic Society clinical practice guideline.
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of chronic obstructive pulmonary disease.
Triple therapy, including glucocorticoid at either of 2 dose levels, is beneficial for moderate-to-very severe chronic obstructive pulmonary disease.
Medication adherence for asthma and chronic obstructive pulmonary disease has increased during the COVID-19 pandemic,
In patients hospitalized for COPD exacerbation, the presence of atrial fibrillation may increase the risk of in-hospital mortality.
In patients with COPD and hypercapnia, the use of home noninvasive positive pressure ventilation compared with no device was significantly associated with improved clinical outcomes but no significant differences in quality of life.
Patients who are socioeconomically disadvantaged are more likely to continue smoking after a COPD diagnosis.
The addition of tiotropium does not reduce COPD exacerbations.